Microbiology and Biotechnology Letters (한국미생물·생명공학회지)

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Urease Inhibition Activity of Zerumbone in vitro

제럼본의 요소가수분해효소 활성 억제 평가

  • Woo, Hyun Jun (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Lee, Min Ho (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Yang, Ji Yeong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kwon, Hye Jin (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Yeon, Min Ji (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Do Hyun (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Moon, Cheol (Department of Clinical Laboratory Science, Semyung University) ;
  • Park, Min (Department of Biomedical Laboratory Science, Daekyeung University) ;
  • Kim, Sa-Hyun (Department of Clinical Laboratory Science, Semyung University) ;
  • Kim, Jong-Bae (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
  • 우현준 (연세대학교 보건과학대학 임상병리학과) ;
  • 이민호 (연세대학교 보건과학대학 임상병리학과) ;
  • 양지영 (연세대학교 보건과학대학 임상병리학과) ;
  • 권혜진 (연세대학교 보건과학대학 임상병리학과) ;
  • 연민지 (연세대학교 보건과학대학 임상병리학과) ;
  • 김도현 (연세대학교 보건과학대학 임상병리학과) ;
  • 문철 (세명대학교 임상병리학과) ;
  • 박민 (대경대학교 임상병리과) ;
  • 김사현 (세명대학교 임상병리학과) ;
  • 김종배 (연세대학교 보건과학대학 임상병리학과)
  • Received : 2017.08.14
  • Accepted : 2017.09.19
  • Published : 2017.09.28
Download PDF
⟨ Previous Next ⟩

Abstract

A key virulence factor for urinary tract pathogens is the enzyme urease, which catalyzes the hydrolysis of urea into ammonium ions and carbonic acid. Urease activity plays an important role in the pathogenesis of urinary tract infection. In this study, the inhibitory effect of zerumbone against six urease-producing bacteria (Klebsiella oxytoca, K. pneumoniae, Morganella morganii, Proteus mirabilis, P. vulgaris, and Staphylococcus saprophyticus) and their urease activities were evaluated. The results of the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) tests showed that zerumbone had antibacterial effect against these six urease-producing bacteria. The MIC and MBC of zerumbone ranged from 0.5 to 2 mM and 1 to 4 mM, respectively. In the urease inhibitory assay, zerumbone showed better urease inhibition ($56.28{\pm}2.45-37.83{\pm}3.47%$) than the standard urease inhibitor, acetohydroxamic acid ($40.46{\pm}1.94-22.99{\pm}3.53%$). However, zerumbone did not affect the levels of the urease subunit. These results clearly indicated that zerumbone has antibacterial potential against urease-producing bacteria and possesses excellent bacterial urease inhibition properties.

요소가수분해효소는 요소를 암모니아와 이산화탄소로 가수분해하는 효소로 요로감염을 일으키는 세균의 주요 병원성 인자이다. 따라서 요소가수분해효소는 세균이 요로감염증을 유발하는데 중요한 역할을 한다. 본 연구에서는 요소가수분해효소를 생성하는 6가지 종류의 세균에 (K. oxytoca, K. pneumoniae, M. morganii, P. mirabilis, P. vulgaris, S. saprophyticus) 대한 제럼본의 억제효과와 요소가수분해효소 활성능을 평가하였다. 최소억제농도와 최소살균농도 실험에서 제럼본은 요소가수분해효소를 생성하는 6가지 종류의 세균에 대해 억제효과를 보였으며, 최소억제농도는 0.5-2 mM, 최소살균농도는 1-4 mM를 나타내었다. 요소가수분해 활성억제 실험에서 제럼본은 요소가수분해효소의 억제제로 사용하는 아세토히드록사민산 보다 뛰어난 요소가수분해 활성억제효과를 보였다. 그러나 제럼본은 요소가수분해효소를 이루는 소단위체의 발현양에는 영향을 주지 않았다. 이러한 결과들을 종합하여 볼 때, 제럼본은 요소가수분해효소를 생성하는 세균에 대한 살균력을 가질 뿐 만 아니라 훌륭한 요소가수분해 활성억제력도 보유하고 있는 것으로 사료된다.

Keywords

References

  1. Murakami A, Takahashi D, Kinoshita T, Koshimizu K, Kim HW, Yoshihiro A, et al. 2002. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha,beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis 23: 795-802. https://doi.org/10.1093/carcin/23.5.795
  2. Ohnishi K, Irie K, Murakami A. 2009. In vitro covalent binding proteins of zerumbone, a chemopreventive food factor. Biosci Biotechnol. Biochem. 73: 1905-1907. https://doi.org/10.1271/bbb.90265
  3. Sulaiman MR, Perimal EK, Akhtar MN, Mohamad AS, Khalid MH, Tasrip NA, et al. 2010. Anti-inflammatory effect of zerumbone on acute and chronic inflammation models in mice. Fitoterapia 81: 855-858. https://doi.org/10.1016/j.fitote.2010.05.009
  4. Prasannan R, Kalesh KA, Shanmugam MK, Nachiyappan A, Ramachandran L, Nguyen AH, et al. 2012. Key cell signaling pathways modulated by zerumbone: role in the prevention and treatment of cancer. Biochem Pharmacol. 84: 1268-1276. https://doi.org/10.1016/j.bcp.2012.07.015
  5. Wahab SIA, Abdul AB, Yeel HC, Alzubairi AS, Elhassan MM, Syam MM. 2008. Anti-Tumor activities of analogues derived from the bioactive compound of Zingiber zerumbet. Int. J. Cancer Res. 4: 154-159. https://doi.org/10.3923/ijcr.2008.154.159
  6. Tsuboi K, Matsuo Y, Shamoto T, Shibata T, Koide S, Morimoto M, et al. 2014. Zerumbone inhibits tumor angiogenesis via $NF-{\kappa}B$ in gastric cancer. Oncol Rep. 31: 57-64. https://doi.org/10.3892/or.2013.2842
  7. Rahman HS, Rasedee A, Yeap SK, Othman HH, Chartrand MS, Namvar F, et al. 2014. Biomedical properties of a natural dietary plant metabolite, zerumbone, in cancer therapy and chemoprevention trials. Biomed Res Int. 2014: 920742.
  8. Chen BY, Lin DP, Wu CY, Teng MC, Sun CY, Tsai YT, et al. 2011. Dietary zerumbone prevents mouse cornea from UVB-induced photokeratitis through inhibition of $NF-{\kappa}B$, iNOS, and $TNF-{\alpha}$ expression and reduction of MDA accumulation. Mol. Vis. 17: 854-863.
  9. Nakamura Y, Yoshida C, Murakami A, Ohigashi H, Osawa T, andUchida K. 2004. Zerumbone, a tropical ginger sesquiterpene, activates phase II drug metabolizing enzymes. FEBS Lett. 572: 245-250. https://doi.org/10.1016/j.febslet.2004.07.042
  10. Jantan I, Raweh SM, Sirat HM, Jamil S, Mohd Yasin YH, Jalil J, et al. 2008. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation. Phytomedicine 15: 306-309. https://doi.org/10.1016/j.phymed.2007.08.002
  11. Khan AW, Jan S, Parveen S, Khan RA, Saeed A, Tanveer AJ, et al. 2012. Phytochemical analysis and enzyme inhibition assay of Aerva javanica for Ulcer. Chem. Cent. J. 6: 76.
  12. Khan H, Khan MA, Hussan I. 2007. Enzyme inhibition activities of the extracts from rhizomes of Gloriosa superba Linn (Colchicaceae). J. Enzyme Inhib. Med. Chem. 22: 722-725. https://doi.org/10.1080/14756360601164853
  13. Lateef M, Iqbal L, Fatima N, Siddiqui K, Afza N, Zia-ul-Haq M, et al. 2012. Evaluation of antioxidant and urease inhibition activities of roots of Glycyrrhiza glabra. Pak. J. Pharm. Sci. 25: 99-102.
  14. Kuwahara H, Miyamoto Y, Akaike T, Kubota T, Sawa T, Okamoto S, et al. 2000. Helicobacter pylori urease suppresses bactericidal activity of peroxynitrite via carbon dioxide production. Infect. Immun. 68: 4378-4383. https://doi.org/10.1128/IAI.68.8.4378-4383.2000
  15. Rosenstein IJ, Hamilton-Miller JM, Brumfitt W. 1981. Role of urease in the formation of infection stones: comparison of ureases from different sources. Infect. Immun. 32: 32-37.
  16. Amtul Z, Rahman AU, Siddiqui RA, Choudhary MI. 2002. Chemistry and mechanism of urease inhibition. Curr. Med. Chem. 9: 1323-1348. https://doi.org/10.2174/0929867023369853
  17. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. Clinical and Laboratory Standards Institute. M07-A9.
  18. Yoo TH, Lee MH, Park M, Lee J, Woo HJ, Kim HW, et al. 2015. Detection of EBV-encoded small RNA from diffuse large B-cell lymphoma patients by RT-PCR method. Biomed Sci Lett. 21: 227-232. https://doi.org/10.15616/BSL.2015.21.4.227
  19. Muhammad N, Saeed M, Khan A, Adhikari A, Wadood A, Khan KM, et al. 2014. A new urease inhibitor from Viola betonicifolia. Molecules 19: 16770-16778. https://doi.org/10.3390/molecules191016770
  20. Bhat RG, Katy TA, Place FC. 2011. Pediatric urinary tract infections. Emerg Med. Clin. North Am. 29: 637-653. https://doi.org/10.1016/j.emc.2011.04.004
  21. Foxman B. 2014. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am. 28: 1-13. https://doi.org/10.1016/j.idc.2013.09.003
  22. Hooton TM. 2012. Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 366: 1028-1037. https://doi.org/10.1056/NEJMcp1104429
  23. Nicolle LE. 2012. Urinary catheter-associated infections. Infect. Dis. Clin. North Am. 26: 13-27. https://doi.org/10.1016/j.idc.2011.09.009
  24. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13: 269-284. https://doi.org/10.1038/nrmicro3432
  25. Nielubowicz GR, Mobley HL. 2010. Host-pathogen interactions in urinary tract infection. Nat. Rev. Urol. 7: 430-441. https://doi.org/10.1038/nrurol.2010.101
  26. Raz R, Colodner R, Kunin CM. 2005. Who are you--Staphylococcus saprophyticus? Clin. Infect. Dis. 40: 896-898. https://doi.org/10.1086/428353
  27. Kosikowska P, Berlicki L. 2011. Urease inhibitors as potential drugs for gastric and urinary tract infections: a patent review. Expert. Opin. Ther. Pat. 21: 945-957. https://doi.org/10.1517/13543776.2011.574615
  28. Zhang L, Mulrooney SB, Leung AF, Zeng Y, Ko BB, Hausinger RP, et al. 2006. Inhibition of urease by bismuth(III): implications for the mechanism of action of bismuth drugs. Biometals 19: 503-511. https://doi.org/10.1007/s10534-005-5449-0
  29. Griffith DP, Gibson JR, Clinton CW, Musher DM. 1978. Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi. J. Urol. 119: 9-15. https://doi.org/10.1016/S0022-5347(17)57366-8
  30. Williams JJ, Rodman JS, Peterson CM. 1984. A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N. Engl. J. Med. 311: 760-764. https://doi.org/10.1056/NEJM198409203111203
  31. Bailie NC, Osborne CA, Leininger JR, Fletcher TF, Johnston SD, Ogburn PN, et al. 1986. Teratogenic effect of acetohydroxamic acid in clinically normal beagles. Am. J. Vet. Res. 47: 2604-2611.
  32. Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N. 1991. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur. Urol. 20: 243-247. https://doi.org/10.1159/000471707
  33. Griffith DP, Khonsari F, Skurnick JH, James KE. 1988. A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J. Urol. 140: 318-324. https://doi.org/10.1016/S0022-5347(17)41592-8

Cited by

  1. Zerumbone 처리에 따른 Helicobacter pylori의 단백질 비교분석 vol.50, pp.3, 2018, https://doi.org/10.15324/kjcls.2018.50.3.275